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The transcription factor Prox1 is essential for
satellite cell differentiation and muscle ﬁbre-type
regulation
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Zoltan Wiener2,w & Kari Alitalo1,2
The remarkable adaptive and regenerative capacity of skeletal muscle is regulated by several
transcription factors and pathways. Here we show that the transcription factor Prox1 is an
important regulator of myoblast differentiation and of slow muscle ﬁbre type. In both rodent
and human skeletal muscles Prox1 is speciﬁcally expressed in slow muscle ﬁbres and in
muscle stem cells called satellite cells. Prox1 activates the NFAT signalling pathway and is
necessary and sufﬁcient for the maintenance of the gene program of slow muscle ﬁbre type.
Using lineage-tracing we show that Prox1-positive satellite cells differentiate into muscle
ﬁbres. Furthermore, we provide evidence that Prox1 is a critical transcription factor for the
differentiation of myoblasts via bi-directional crosstalk with Notch1. These results identify
Prox1 as an essential transcription factor that regulates skeletal muscle phenotype and
myoblast differentiation by interacting with the NFAT and Notch pathways.
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A
dult skeletal muscles regenerate after damage due to the
proliferation and differentiation of muscle resident stem
cells called satellite cells (SC). In healthy resting muscle
these cells are in a quiescent state, which is characterized by a
reversible mitotic arrest and slow metabolic activity indicative of
many stem cell populations1. In response to muscle injury, SCs
can be activated, resulting in proliferation, differentiation and
self-renewal2. Members of the MyoD family of myogenic
regulatory factors (MyoD, Myogenic factor 5 (Myf5), Myogenic
factor 6/Mrf4 and myogenin) control the formation of skeletal
muscle and muscle regeneration in the adult2. The paired box
factors Pax3 and Pax7 are important upstream regulators of the
myogenic regulatory factors in SCs and the differentiation of
committed myoblasts require the downregulation of Pax7
(refs 3,4). However, the molecular mechanisms underlying SC
activation and differentiation are not completely understood.
Skeletal muscle ﬁbres can be classiﬁed by their contraction
speed and their aerobic (oxidative) versus anaerobic (glycolytic)
production of ATP5. Slow type I ﬁbres express myosin heavy
chain I (Myh7, MyHC I), use aerobic metabolism, are rich in
mitochondria and myoglobin, and have good endurance. In
contrast, type IIB fast twitch ﬁbres, which express Myh4/MyHC
IIB, are primarily anaerobic and glycolytic, contain many
glycogen granules, and contract quickly for short-term activity.
In addition, the oxidative type IIA (Myh2/MyHC IIA) and
intermediate type IIX (Myh1/MyHC IIX) fast twitch ﬁbres have
intermediate contraction properties compared with type I and IIB
ﬁbres.
The prospero-related homeobox 1 (Prox1) transcription factor,
especially its homeo-prospero domain, is highly conserved among
vertebrates6–8. Prox1 is essential for the development of several
organs; Prox1-deﬁcient mice die before birth due to multiple
developmental defects9. A role for Prox1 in the development of
lymphatic vasculature, liver, pancreas, heart and lens has been
shown in previous studies9–13. Some studies have suggested a role
for the Prox1 in skeletal muscle development and ﬁbre type
speciﬁcation14–16. In zebraﬁsh, the U-boot (Ubo) gene, which
regulates slow versus fast ﬁbre differentiation pathways, activates
Prox1 in slow myoblasts. This is crucial for the terminal stages of
ﬁbre development and for their proper organization in slow
ﬁbres14. Recently, Petchey et al.16 demonstrated in mice that
Prox1 is required for the repression of fast troponin T3, troponin
I2, and myosin light chain 1 in both cardiac and skeletal muscle,
indicating conservation of Prox1 function in vertebrates15.
Here we assess the role of Prox1 in the regulation of skeletal
muscle phenotype and function. We show that Prox1 is expressed
in rodent and human slow muscle ﬁbres and in SC. In SC, Prox1
expression is induced on differentiation, and Prox1 silencing
results in Notch1 activation and inhibition of myoblast
differentiation. Interestingly, Prox1 is also necessary and
sufﬁcient for the slow ﬁbre type gene program via regulation of
NFAT signalling.
Results
Prox1 is expressed in slow muscle ﬁbres and SC. Prox1
expression in skeletal muscle has been reported in zebraﬁsh and
mice14–16. Our results show that human skeletal muscle ﬁbres
express Prox1 and, interestingly, we observed nuclear Prox1
immunostaining only in the nuclei of muscle ﬁbres that express
the slow MyHC I in all mouse, rat and human skeletal muscles
studied (Fig. 1a,b). The Prox1-positive nuclei were located under
the basal lamina, indicating that they were muscle ﬁbre nuclei.
Furthermore, Prox1 was not expressed in blood vascular
endothelial cells. We compared Prox1 expression in different
rat muscles, and observed the highest Prox1 mRNA levels in the
soleus muscle (SOL), which predominantly consists of type I slow
ﬁbres, followed by the red part of the gastrocnemius muscle
(RGA) enriched for type IIA ﬁbres (Fig. 1c). In contrast, Prox1
expression was only marginal in the tibialis anterior (TA) and the
white part of the gastrocnemius muscle (WGA), both containing
mainly fast IIB ﬁbres. Mouse and rat skeletal muscles contain
fewer slow ﬁbres than most human muscles and, in accordance
with this, fewer Prox1-positive nuclei were observed in rodent
muscles than in human muscles (Fig. 1).
b
MyHC I +Prox1+DAPI Prox1 a
c
0.5
1.0
1.5
**
***
***
Prox1 mRNA
(relative expression
SOL=1)
SOL RGA WGA TA
R
at
 ti
bi
al
is 
an
te
rio
r m
us
cle
MyHC I  + Prox1 + DAPI
CD31 + Prox1 + LamininMyHC I + Prox1 + Laminin
H
um
an
 v
as
tu
s 
la
te
ra
lis
 m
us
cl
e
Figure 1 | Prox1 expression in slow muscle ﬁbres in mammalian skeletal
muscle. (a) Prox1 expression in the nuclei (magenta) of slow muscle ﬁbres
stained for MyHC I (green) in human vastus lateralis muscle. Co-staining
with laminin indicates that the Prox1 positive nuclei are under the basal
lamina of the muscle ﬁbres (arrows). Note that Prox1 staining does not
co-localize with endothelial cells (CD31, arrows). (b) Prox1 positive nuclei
(magenta) in MyHC I (green) positive slow muscle ﬁbres in rat tibialis
anterior muscle. Few Prox1 positive nuclei were found also in the proximity
of fast ﬁbres. (c) Prox1 mRNA expression in various rat skeletal muscles.
Note the highest expression in the slow soleus (SOL) muscle. RGA, red
gastrocnemius; TA, tibialis anterior; WGA, white gastrocnemius. Data is
presented as mean±s.e.m., n¼4, one-way analysis of variance with
Tukey’s post hoc test, **Po0.01, ***Po0.001 compared with soleus.
Scale bars, 50mm.
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In addition, we observed mononuclear MyHC I-negative cells
expressing Prox1 in the skeletal muscle. Staining of rat TA muscle
sections for the SC markers Pax3 and Pax7 with Prox1 indicated
that these cells have SC identity (Fig. 2a), raising the possibility
that Prox1 has a role in the regulation of muscle stem cells as well.
We further conﬁrmed our ﬁnding in human skeletal muscles,
where Pax7 and NCAM (CD56) positive SCs expressed Prox1
(Fig. 2b), with 98% of Pax7þ nuclei being Prox1 positive
(81 out of 83 cells) (Fig. 2c).
Prox1 expression is necessary for the slow muscle phenotype.
Since Prox1 was abundantly expressed in slow muscle ﬁbres, we
next assessed the function and downstream signalling of Prox1 in
skeletal muscles. Adeno-associated viral vector (AAV8) encoding
Prox1 was injected into mouse TA muscle, which is composed of
fast muscle ﬁbres with very low endogenous Prox1 expression.
The contralateral muscle was injected with AAV encoding
mCherry reporter protein equipped with a nuclear localization
signal. Although the overall muscle structure was not affected by
Prox1 overexpression, after four weeks we observed occasional
cells expressing MyHC I (Fig. 3a), which were not found in the
control TA muscles (MyHC I staining in 6.6 % of all ﬁbres and
25.4 % of Prox1 overexpressing ﬁbres).
Prox1 transduction to fast skeletal muscle resulted in the
activation of the slow muscle ﬁbre speciﬁc gene program
involving contractile elements and calcium regulation (Myh7,
TnnC1, TnnCI1, Myoz2, Sln), while downregulating fast MyHC
genes (Myh2 and Myh4; Fig. 3b). Furthermore, Gene Set
Enrichment Analysis (GSEA) from whole-genome microarray
analysis revealed a strong induction of soleus/slow ﬁbre-speciﬁc
genes (Fig. 3c). However, Prox1 targets in skeletal muscle were
tissue-speciﬁc without signiﬁcant overlap with genes regulated by
Prox1 in colorectal cancer17,18 (Supplementary Fig. 1a).
To test if Prox1 is necessary for the slow ﬁbre program, we
deleted Prox1 in skeletal muscle ﬁbres by administering
tamoxifen to HSA-CreERT2;Prox1ﬂ/ﬂ adult mice (indicated as
Prox1D in ﬁgures). We used the human a-skeletal actin (HSA)
promoter-driven Cre-recombinase, which is expressed speciﬁcally
in skeletal muscle ﬁbres19 to delete Prox1 in skeletal muscles
(Supplementary Fig. 2a). Prox1 deletion resulted in increased
expression of fast MyHC genes and downregulation of typical
slow ﬁbre genes in soleus muscle (Fig. 3d). As additional
evidence, we deleted Prox1 via injection of AAV8-Cre vector into
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Figure 2 | Prox1 is expressed in rodent and human satellite cells. (a) Prox1 colocalization with Pax3 and Pax7 positive satellite cells (arrows) in quiescent
rat tibialis anterior muscle. (b) Prox1 colocalization with Pax7 and NCAM positive satellite cells (arrows) in human vastus lateralis muscle. (c) A bar graph
showing the percentage of Prox1þ cells amongst Pax7þ /Dapiþ cells in human vastus lateralis muscle. A total of 83 cells were analysed from ﬁve
subjects. Scale bars, 50mm.
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Figure 3 | Prox1 regulates the slow muscle ﬁbre gene program in skeletal muscle. (a) MyHC I (Myh7) expression in muscle ﬁbres (arrows) in
AAV8-Prox1 and AAV8-Ctrl transduced TA muscle. (b) Expression of myosin heavy chain and calcium-signalling genes in AAV8-Prox1 and AAV8-Ctrl
transduced TA muscle. Note that the expression of slow ﬁbre -speciﬁc genes are upregulated and fast MyHC genes downregulated in Prox1 overexpressing
muscles. (c) Heat map from GSEA analysis showing that Prox1 overexpression in TA muscle leads to expression of many soleus speciﬁc myoﬁbrillar genes
(red colour indicates positive and blue negative enrichment). (d) Effect of Prox1 deletion on soleus muscle gene expression (HSA-CreERT2;Prox1ﬂ/ﬂ mice).
Note the increased expression of fast MyHCs Myh2 and Myh4 RNAs, whereas slow troponin isoform RNAs and Myh7 RNA are decreased. (e) Deletion of
Prox1 in slow soleus muscle with AAV-Cre leads to marked downregulation of MyHC I protein. Data is presented as mean±s.e.m., n¼ 5þ 5 in a,b,
n¼ 3þ 3 in c, n¼4þ4 in d,e. Student’s two-tailed unpaired t-test, *Po0.05, **Po0.01, ***Po0.001. Both overexpression and deletion experiments were
conducted two times on independent mouse cohorts. WT, wild-type. Scale bars, 50mm.
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the soleus muscles of Prox1ﬂ/ﬂ mice. This led to a robust decrease
of MyHC I protein level in the soleus muscle after three weeks
(Fig. 3e, Supplementary Fig. 6a). Collectively, these results
showed that Prox1 expression is necessary and sufﬁcient for the
slow muscle ﬁbre gene expression program. Furthermore,
Prox1-deﬁcient mice had a signiﬁcantly impaired exercise
capacity, as they ran only half of the distance compared with
wild-type littermates in a maximal graded exercise test
(Supplementary Fig. 2b). In the gastrocnemius muscles of
wild-type mice, the expression of Prox1 was decreased after an
acute maximal exercise (Supplementary Fig. 2c).
There is a dramatic change in the expression levels of
different MyHCs during the ﬁrst weeks after birth, which was
also detected in our experiments (Supplementary Fig. 2d).
Surprisingly, however, Prox1 expression in mouse skeletal
muscle remained constant during the ﬁrst three weeks of
postnatal life (Supplementary Fig. 2d), suggesting that Prox1
expression is relatively stable during postnatal muscle growth and
development.
Prox1 activates NFAT signalling in vivo and ex vivo.
Calcineurin/ Ca2þ -dependent nuclear factor of activated T cells
(NFAT) pathway is a key regulator of slow muscle ﬁbre
phenotype20. GSEA analysis of the whole-genome transcriptome
from Prox1 overexpressing muscles showed a highly signiﬁcant
induction of the genes that are upregulated by NFAT activity,
suggesting that Prox1 exerts its effects via this pathway.
Consistently, we found that genes repressed by NFAT signalling
were downregulated in muscles with Prox1 overexpression
(Fig. 4a). In particular, a signiﬁcant upregulation of Rcan1,
which is speciﬁcally increased on activation of calcineurin21, was
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Figure 4 | Prox1 acts by activating NFAT signalling. (a) Heat maps from GSEA analysis showing that Prox1 overexpression induces the expression of
genes known to be upregulated by calcineurin/NFAT signalling (red for upregulation compared with control) and decreases the expression of majority of
genes downregulated by calcineurin/NFAT signalling (blue for downregulation compared with control). (b) qPCR analysis of regulator of calcineurin-1
(Rcan1) in Prox1 transduced TA muscles and Prox1 deﬁcient soleus muscles. (c) NFAT-luciferase reporter assay in C2C12 cells transduced with retroviral
(RV) Prox1 or GFP. (d) Nfatc1 staining in C2C12 cells overexpressing Prox1. (e) Nfatc1–3 mRNA expression in wild-type and Prox1 deleted soleus muscles
Data is presented as mean±s.e.m. n¼ 3þ 3 in a,c, n¼ 5þ 5 and 4þ4 in b, n¼ 3þ 3 in d (repeated three times). Student’s two-tailed unpaired t-test,
*Po0.05, ***Po0.001. Scale bar, 50mm.
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detected in the Prox1 overexpressing TA muscles. A decreased
Rcan1 expression trend (P¼ 0.07, Student’s two-tailed t-test) in
the Prox1 deﬁcient soleus muscles was also observed (Fig. 4b). In
addition, Prox1 repressed the expression of key genes inhibiting
NFAT activity, such as the muscle-speciﬁc calcineurin inhibitor
myospryn/Cmya5 (ref. 22) (log2 FC  0.33, false discovery rate
(FDR)¼ 0.007) and calsarcin-2/Myoz123 (log2 FC  0.70,
FDR¼ 0.03). On the other hand, the expression of a-actinin-2,
which competes with calcineurin for binding to calsarcin-2
(ref. 24) and thus functions as a positive regulator of NFAT, was
signiﬁcantly increased (log2 FC 0.66, FDR¼ 0.01). The genes
with the most signiﬁcantly changed expression (FDRo0.001) in
AAV-Prox1-treated muscles are listed in Supplementary Dataset.
To test whether Prox1 regulates NFAT activity, we transduced
C2C12 myoblasts with a retroviral Prox1 expression vector and
subsequently the cells were transfected with an NFAT-luciferase
reporter. Prox1-increased luciferase activity in C2C12 cells,
indicating that it activates NFAT signalling in myoblasts
(Fig. 4c). Immunostaining showed that Prox1 induces nuclear
translocation of Nfatc1, reﬂecting its activation (Fig. 4d).
Consistent with this ﬁnding, western blotting demonstrated
increased cytoplasmic Nfatc1 in Prox1 silenced cells when
compared with controls, indicating reduced nuclear translocation
of Nfatc1 (Supplementary Figs 3 and 6b). Furthermore, the
expression levels of Nfatc1, Nfatc2 and Nfatc3 were down-
regulated in Prox1 deleted soleus muscles (Fig. 4e). We conclude
that Prox1 is involved in the activation of the NFAT pathway and
several of its downstream genes in skeletal muscle.
The Prox1-positive SCs act as stem cells after muscle injury.
Since Prox1 was detected in SC in addition to mature slow muscle
ﬁbres, we set out to assess the importance of Prox1 in SC pro-
liferation and differentiation. First, to test the stem cell properties
of the Prox1-positive mononuclear cells in skeletal muscle,
we used a lineage tracing approach in Prox1-CreERT2;
Rosa26TdTomatoﬂ/STOP/ﬂ mice. In this model, a single tamoxifen
injection induces Cre activity and results in the removal of a
transcriptional stop cassette in front of the tdTomato reporter
coding sequence, thus leading to the expression of the red
ﬂuorescent protein exclusively in the Prox1-positive cells and
their progenies. Cardiotoxin was injected into the TA muscles to
induce muscle injury. As the mouse TA does not contain slow
ﬁbres, the Prox1-positive cells in this muscle are SC or lymphatic
endothelial cells. After 1 and 4 days, we detected a marked
inﬂammation and degenerating muscle ﬁbres (Fig. 5a). At day 4,
the number of TdTomato-positive mononuclear cells was
increased in the damaged area, and some of these cells were
positive for the proliferation marker Ki67 (Supplementary Fig. 4).
At day 22, the cardiotoxin-treated muscles had regenerated and
several ﬁbres expressed red ﬂuorescence, demonstrating that they
originated from Prox1-positive SCs (Fig. 5b). However, the nuclei
of these ﬁbres became Prox1 negative and they did not stain for
MyHC I, indicating that they had acquired the fast ﬁbre pheno-
type typical for TA muscle (Fig. 5c). Muscle ﬁbres with red
ﬂuorescence were not found in any of the PBS injected muscles.
To increase the labelling efﬁciency, we injected tamoxifen twice
before CTX, which resulted in tdTomato labelling of most of the
regenerated ﬁbres three weeks after injury (Fig. 5d). Altogether,
these data show that Prox1-positive SCs display stem cell
behaviour under regenerative conditions.
Prox1 is critical for myoblast differentiation. To further test the
role of Prox1 in SCs, we studied the mouse C2C12 myoblast cell
line and primary human myoblasts. These cells can differentiate
into myotubes with multiple nuclei, thus displaying stem cell
features. Prox1 expression was strongly increased during mouse
and human myoblast differentiation both at the mRNA and
protein level (Fig. 6a,b). Silencing Prox1 by lentiviral shRNA
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Figure 5 | Lineage-tracing experiment of Prox1 expressing satellite cells. (a) HE staining of cardiotoxin-treated (CTX) and PBS-injected muscles
showing the degeneration and regeneration processes 1, 4 and 22 days after CTX-injection. (b) Prox1 staining and TdTomato ﬂuorescence 22 days after
CTX-injection. Note several Prox1 negative red ﬁbres, indicating that the Prox1 expressing satellite cells have differentiated into Prox1 negative muscle
ﬁbres. No red muscle ﬁbres were found in the PBS-treated muscles. Arrows point to Prox1 and tdTomato-positive SCs. (c) The regenerated tdTomato
positive muscle ﬁbres originating from Prox1-positive SCs were MyHC I negative in fast tibialis anterior muscle. (d) TdTomato-positivity obtained with two
tamoxifen injections; one injection was used in the experiments of a–c. Note that most of the regenerated ﬁbres are red. Scale bars, 100mm.
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signiﬁcantly affected the expression of Myod1 and Myf5 in
undifferentiated and differentiated human myoblasts (Fig. 6c,d)
as well as in C2C12 cells (Fig. 6e,f). This resulted in a dysregulated
differentiation of the myoblasts, evidenced by the lack of myosin-
positive multinucleated myotubes (Fig. 6g). In addition, we found
that CyclinD1 (Ccnd1) mRNA level and the proliferation of
Prox1 silenced cells were signiﬁcantly elevated (EdU positive
C2C12 cells after 4 h: shProx1 47.5±1.2 % versus shScr 37.8±0.6
%, Po0.001, Student’s two-tailed t-test), (Fig. 6d–f).
Bidirectional regulation between Prox1 and Notch1. Notch
signalling activity is crucial in maintaining SC quiescence and
preventing premature muscle differentiation25–27. Since our
results showed that Prox1 is needed for the differentiation of
myoblasts that have stem cell features, we studied if Prox1
modulates Notch signalling. We ﬁrst tested if Prox1 regulates
Notch signalling activity in C2C12 cells transfected with a
CSL-luciferase reporter (for monitoring general Notch activity) or
Notch1-speciﬁc luciferase reporter. Prox1 silencing signiﬁcantly
increased Notch activity in both assays, indicating that Prox1
represses Notch1 signalling (Fig. 7a). To test the functional
domains of Prox1 that are needed for repression of Notch
signalling, we transduced myoblasts with lentiviral constructs for
wild-type Prox1 or the N-terminal domain of Prox1 lacking the
DNA binding domain, and tested their effects on CSL- and
Notch-luciferase activities. The results indicated that the
N-terminal part of Prox1 was sufﬁcient to suppress Notch1-
activity, thus direct interaction with DNA was not required
(Fig. 7b). Similar results were also obtained with transient
transfection of these constructs (Supplementary Fig. 5a). We then
investigated if this regulation occurs in vivo in skeletal muscle.
Prox1 overexpression in mouse skeletal muscle resulted in
signiﬁcant downregulation of several Notch signalling-related
genes (Fig. 7c).
Notch and its downstream effectors Hey1 and Hey2 were
shown to regulate Prox1 in lymphatic endothelial cells28. Thus,
we next tested if Notch activity regulates Prox1 expression
in myoblasts. Human primary myoblasts transduced with
Ad-hNotch1 exhibited decreased Prox1 expression, whereas
inhibition of Notch signalling by administration of the gamma-
secretase/Notch cleavage inhibitor DAPT tended to increase
Prox1 expression (Fig. 7d and Supplementary Fig. 5b). Notch1
also increased CyclinD1 and decreased MyoD1 expression, which
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Figure 6 | Prox1 regulates myoblast differentiation. (a) Analysis of Prox1 mRNA and protein during C2C12 myoblast differentiation (indicated by the
increase in MyoD1 mRNA). (b) Prox1 protein and mRNA in human myoblasts before and after differentiation. Primary myoblast lines from two different
individuals were analysed. (c–f) Analysis of myoblast proliferation and differentiation-related CyclinD1, Myf5 and MyoD mRNAs in shProx1 and shScr
transduced primary human myoblasts before (c) and after differentiation for 7d (d), as well as in mouse C2C12 myoblasts before (e) and after
(f) differentiation. (g) Myosin staining of C2C12 cells after 7d of differentiation. Note that Prox1 silencing completely blocked myotube development,
as only occasional cells expressed myosin and these cells were negative for shProx1-GFP. Data is presented as mean±s.e.m., n¼ 3þ 3 biological replicates
in a–g (all experiments were repeated three times). One-way analysis of variance with repeated measures followed by Tukey’s posthoc test and Student’s
two-tailed unpaired t-test, *Po0.05, **Po0.01, ***Po0.001. Scale bars, 50mm.
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are needed to sustain cells in proliferating and undifferentiated
state, respectively. To test if Prox1 expression is regulated by
canonical Notch signalling, we silenced both Hey1 and Hey2
in human myoblasts, and found that this abolished the
Notch1-induced decrease of Prox1 expression (Fig. 7e). These
data suggest that high Notch activity in quiescent and
proliferating SCs inhibits Prox1 expression, and that during
differentiation, when Notch activity decreases, Prox1 expression
is induced. Collectively, these results identify Prox1 as an essential
transcription factor required for myoblast differentiation via
bidirectional interaction with Notch1.
Discussion
In this study we identiﬁed the transcription factor Prox1 as a
critical regulator of SC differentiation and muscle ﬁbre phenotype
in rodents and humans. Prox1 was necessary and sufﬁcient for
the slow ﬁbre type gene program by regulating NFAT signalling
and essential for myoblast differentiation by reciprocal regulation,
with Notch, (see the schematic in Fig. 8).
Our results show that Prox1 is expressed only in the nuclei of
MyHC I positive slow muscle ﬁbres, but not in the fast muscle
ﬁbres. In a recent study, Prox1 was shown to suppress fast ﬁbre
genes in the heart and skeletal muscle, but the authors suggested
that this occurs in all muscle ﬁbre types16. We demonstrate here
that Prox1 is able to initiate the slow muscle ﬁbre program when
transduced into fast muscles and that Prox1 deletion suppresses
slow and induces fast ﬁbre genes. Plasticity for ﬁbre type switch
can be activated in adult muscles by the previously identiﬁed
Mef2, NFAT and myogenin transcription factors, which play
a role in the determination of ﬁbre-type characteristics20,29,30.
The NFAT pathway, especially Nfatc1, has been demonstrated to
be essential for slow ﬁbre-type determination31–33. Our whole-
genome RNA expression analysis of Prox1 overexpressing
muscles indicated NFAT pathway activation, thus accounting
for the ability of Prox1 to induce slow muscle ﬁbre genes.
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Figure 7 | Bidirectional regulation between Prox1 and Notch1 in myoblasts. (a) Notch luciferase activity in C2C12 cells transduced with lentiviral shScr or
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Furthermore, Prox1 deletion resulted in decreased expression
of Nfatc1–3 in skeletal muscle. Prox1 acts mainly as a
transcriptional repressor34, which is in line with the observed
downregulation of the main inhibitors of NFAT signalling in
Prox1 overexpressing muscles. These ﬁndings were further
substantiated by results from the cultured C2C12 myoblasts,
where Prox1-induced Nfatc1 nuclear translocation and NFAT
transcriptional activation. In line with our results, Prox1 has been
shown to be essential for shear stress-induced NFAT activation in
lymphatic endothelial cells35. Thus, our results provide novel
evidence that Prox1 regulates muscle ﬁbre phenotype via NFAT
signalling.
In addition to slow muscle ﬁbres, Prox1 is expressed in most, if
not all, SCs and its expression is induced during myoblast
differentiation. With lineage tracing we obtained evidence
that Prox1-positive cells regenerate into muscle ﬁbres after
cardiotoxin-induced muscle injury. To reveal the signiﬁcance of
Prox1 in SCs, we silenced Prox1 in human primary myoblasts
and in mouse C2C12 myoblasts. This resulted in dysregulated
expression of myogenic factors and in complete inhibition of
differentiation. Several factors, such as Pax3, Pax7 and MyoD
family members, have been shown to be involved in the
regulation of SC properties (reviewed in ref. 2). They act in
concert at different stages of SC self-renewal and differentiation.
Our ﬁndings identify Prox1 as a new important regulator of SC
differentiation.
Notch signalling is critical for skeletal myogenesis and it has an
important role in maintaining the muscle stem cell pool by
blocking myogenic differentiation and preventing premature
muscle differentiation25–27. After muscle injury, SCs start to
proliferate and some of them will differentiate into myoﬁbres
concomitantly with downregulation of Notch, while others
resume a quiescent state36. Our results indicate a bidirectional
negative regulation between Prox1 and Notch1 in myoblasts and
in skeletal muscle, which ﬁts nicely with their sequential
expression patterns during the transition from SC quiescence
to differentiation. Deletion of the C-terminal DNA binding
domain (homeobox and prospero domains) of Prox1 was not
sufﬁcient to relieve the Prox1-mediated suppression of Notch1
promoter activity, indicating that Prox1 inﬂuences Notch1 as
transcriptional co-repressor via (an)other factor(s).
In neuronal progenitor cells, Prox1 has been shown to regulate
the Notch1-mediated inhibition of neurogenesis and to directly
interact with chromatin at the Notch1 promoter37. Similarly to
our ﬁndings, the DNA binding domain of Prox1 was not needed
for the repression of Notch1 activity in neuronal progenitor
cells, and the nuclear receptor LHR-1/NR5A2 was identiﬁed
as a binding partner of Prox1 on the Notch1 promoter.
LHR-1/NR5A2 is also expressed in C2C12 cells38 and skeletal
muscles (unpublished ﬁndings of RK and KA), thus it may serve
as a binding partner for Prox1 in SC as well. We have recently
shown that Prox1 is essential for the expansion of the stem cell
pool in intestinal tumours, where its deletion reduced the number
of stem cells17. Together, our results and previous ﬁndings
suggest that Prox1 is an important regulator of stem cell
behaviour in various tissues.
The present results identify Prox1 as an important factor in
skeletal muscle SC differentiation and show that Prox1 is an
integral part of the slow muscle ﬁbre program. Our results open
up new directions to study and to manipulate SC behaviour
during regeneration, and to understand better the role of Prox1 in
muscle diseases and aging.
Methods
Animal experiments. All mice used in the experiments were maintained in the
C57Bl/6J background. Animal experiments were approved by the Regional State
Administrative Agency for Southern Finland. Mice were housed in individually
ventilated cages with enrichment materials in a facility monitored by the
Federation of European Laboratory Animal Science Associations guidelines and
recommendations.
The Prox1ﬂ/ﬂ (from Dr G. Oliver) and Human Skeletal Actin-MerCreMer
(HSA-CreERT2, from Dr K. Esser) mice were crossed to generate skeletal muscle
ﬁbre speciﬁc Prox1-deﬁcient mice (Prox1D). These mouse lines have been
described previously19,39. To delete Prox1 from skeletal muscles, 8–10 weeks old
male mice were given tamoxifen i.p. (80mg/kg) for ﬁve consecutive days. The
muscles were collected and analysed after two months of deletion. The experiment
was performed twice with independent cohorts (n¼ 4þ 4 and n¼ 6þ 8). To delete
Prox1 only in soleus muscle, AAV9-Cre or empty vector (30 ml per muscle,
6.96 109 vpml 1) were injected into soleus muscles of Prox1ﬂ/ﬂ mice (n¼ 3þ 4
and in a second experiment n¼ 5þ 6).
For overexpression of Prox1 in fast skeletal muscle, 8 weeks old C57Bl/6J
male mice (C57Bl/6JOlaHsd from Harlan) were anaesthetized and recombinant
adeno-associated viral vector (AAV8) encoding Prox1 was injected into mouse TA
muscle (30 ml per muscle, 6.06 109 vpml 1). The contralateral muscle was
injected with AAV8 encoding mCherry reporter protein equipped with a nuclear
localization signal. The experiment was performed twice with independent cohorts
(n¼ 3þ 3 and n¼ 5þ 5).
Whole calf muscle complex was collected from wild-type mice at postnatal days
0, 7 and 21 to study the expression of Prox1 during postnatal development
(n¼ 3 for each time point).
To investigate the role of Prox1 in SC, we performed lineage-tracing
experiments. Prox1-CreERT2 mice40 (from Dr G. Oliver) were crossed with
Rosa26-tdTomatoﬂ/Stop/ﬂ (Jackson Laboratories, Stock 007914) reporter mice.
To label a subset of Prox1 positive cells, mice were given one tamoxifen dose (3mg)
at the same time when cardiotoxin (50 ml of 10 mM) was injected into TA muscle.
PBS was injected into the contralateral muscle. Muscles were collected and
analysed 1, 4 and 22 days after the injection (n¼ 4 muscles/time point/treatment).
In another experiment, we increased the tamoxifen dose to get more efﬁcient
labelling and gave two injections one and two days before cardiotoxin
administration.
Maximal endurance running exercise test was performed on a rodent treadmill
(Panlab) according to the following protocol: 9mmin 1 for 5min, 12mmin 1
for 5min, 15mmin 1 for 5min, 18mmin 1 for 5min and 20mmin 1 until
exhaustion (10 incline). Adaption training session was performed two times
before the experiment.
In all experiments using wild-type mice, mice were randomized into the
experimental groups based on their body weight. The investigators were blinded to
group allocation during experiments.
Soleus, gastrocnemius and tibialis anterior muscles were collected from three
months old male wild-type rats for RNA and immunohistochemical analyses
(n¼ 4).
Cell culture. The mouse myoblast cell line C2C12 (ATCC) was cultured in growth
medium (DMEM high glucose) containing 10% fetal bovine serum (FBS), 2mM
L-glutamine, penicillin (100Uml 1) and streptomycin (100Uml 1). Cells were
differentiated for 4, 6, 7 and 8 days for further experiments. Differentiation
medium contained (DMEM high glucose), 1–2% horse serum (HS), 2mM
L-glutamine, penicillin (100Uml 1) and streptomycin (100Uml 1).
The isolation of SC and preparation of primary human myotubes were
conducted as described previously41. In brief, a muscle biopsy of about 100mg was
taken under local anaesthesia with lidocaine (10mgml 1, without epinephrine)
from the vastus lateralis muscle of healthy men. The tissue was dissected into small
pieces followed by trypsinization in a shaking water bath at 37 C. SC were then
isolated and maintained in DMEM-F12 culture medium containing 20% FBS, 1%
penicillin, 1% streptomycin, and 1% fungizone. Primary myoblasts were selected
via magnetic cell separation using the CD56 antibody (Miltenyi Biotec). To obtain
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Figure 8 | Schematic summary of the pathways regulated by Prox1 in
mature skeletal muscle ﬁbres and satellite cells. Prox1 is expressed in
mature slow muscle ﬁbres, where it regulates NFAT signalling and muscle
ﬁbre type gene programs. Prox1 is also expressed in satellite cells, where it
interacts with Notch signalling pathway, and it is essential for myoblast
differentiation.
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myotubes, myoblasts of 80% conﬂuence were switched to differentiation medium
containing 2% FBS for 7 days. The human study was approved by the Ethical
Committee of Department of Medicine, Helsinki University Central Hospital and
written informed consent was obtained from all participants.
Lentiviral Prox1 silencing construct (shProx1) and scramble control (shScr)
were from the TRC1 library for human myoblasts (Sigma-Aldrich)17. For mouse
myoblasts we used shProx1 constructs from TRC1 and TRC2 (TRCN0000070723,
TRCN0000070724, TRCN0000420735, TRNC0000425447, TRCN0000432522
from Sigma-Aldrich). The lentivirus-containing supernatant of 293FT cells was
concentrated, and cells were transduced overnight with polybrene (Sigma,
8 mgml 1). After transduction, cells were further selected with 3 mgml 1 (human
myoblasts) or 30 mgml 1 (C2C12) puromycin (Sigma). After selection, the cells
were cultured for further experiments. Retroviral constructs for Prox1 and GFP
(control) were used for transfection of undifferentiated C2C12 cells overnight,
followed by recovery for two to three days before the experiments.
Prox1-overexpressing and -silenced cells were transfected with expression
plasmids encoding the NFAT-luciferase reporter (NFAT/AP-1 3 luciferase was a
gift from Anjana Rao, Addgene plasmid #11783), Notch reporter CSL-luciferase
reporter (4xCSL-luciferase was a gift from Raphael Kopan, Addgene plasmid #
41726) or Notch1-luciferase reporter37,42 (gift from Tohru Kiyono) by using the
jetPEI reagent (Polyplus transfection). TK-Renilla luciferase was used as a
transfection control. Promega’s dual luciferase assays were performed according to
the manufacturer’s instructions. All experiments were done in quadruplicate and
repeated at least 2–4 times.
To analyse the effect of Notch signalling activity on Prox1 expression, we
transduced primary human myoblasts with adenoviral constructs encoding human
Notch1 or GFP as a control. To inhibit Notch activity, the cells were treated with
gamma-secretase inhibitor DAPT (10 mM). Prox1 expression was analysed after
2–3 days of treatment. To silence Hey1 and Hey2 in human myoblasts, lentiviral
vectors were produced from TRC1 library constructs (TRCN00000202014 and
TRC0000020249, Sigma-Aldrich).
For generation of the PROX1 mutant without DNA binding domain
(PROX1-deltaHP), the stop codon was introduced after nucleotides encoding
Ser569 (XP_005273251.1|) in the construct encoding a MYC-tagged wild type
human PROX1 in the lentiviral vector pSD44 (ref. 43) using standard site-directed
mutagenesis procedures. The presence of mutation was conﬁrmed by sequencing,
and protein truncation and equivalent wild type and mutant protein production
levels were veriﬁed by western blot analysis.
RNA extraction and quantitative real-time PCR. Cells were lysed and total RNA
was extracted with Nucleospin RNA II Kit (Macherey-Nagel). Muscle tissues were
ﬁrst lysed with Trisure reagent (Bioline) and RNA was further extracted with the
Nucleospin RNA II Kit (Macherey-Nagel). cDNA synthesis was performed with
the iScript cDNA synthesis kit (Bio-Rad) using 1 mg RNA and random
hexamer primers. qRT-PCR was performed with the iQ SYBR green supermix
(Bio-Rad). Relative gene expression levels were calculated using the formula
2DDCt. Primers are listed in Supplementary Table 1.
Whole-genome microarray. The quality of RNA was determined with
Bioanalyzer (Agilent Technologies) and analysed on genome-wide Illumina Mouse
WG-6 v2 Expression BeadChips (Illumina). Illumina’s GenomeStudio software was
used for initial data analysis and quality control and the further data analysis was
performed with the Chipster software (www.chipster.csc.ﬁ)44. After quantile
normalization, statistically signiﬁcant differences in individual genes between the
groups were tested using Empirical Bayes statistics and the Benjamini-Hochberg
algorithm controlling FDR. Adjusted FDR values of Po0.05 were considered
signiﬁcant. The microarray data have been submitted to the GEO database, under
the series accession number GSE69199.
Gene set enrichment analysis. The gene expression dataset was transferred to the
Gene Set Enrichment Analysis software (http://www.broadinstitute.org/gsea)45,46
and the analysis was carried out with default parameters except that the ‘exclude
smaller sets’ was set to 25 and gene permutation was applied. We used a modiﬁed
list of the kegg.v3.1.symbols gene set (http://www.broadinstitute.org/gsea/msigdb),
with the addition of slow muscle ﬁbre-speciﬁc genes47 and Prox1 target genes in
colorectal cancer18. FDR Q value o0.1 was regarded signiﬁcant.
Polyacrylamide gel electrophoresis and western blotting. Cells were lysed with
cold RIPA buffer (50mM Tris-HCl at pH7.6, 150mM NaCl, 1% NP-40, 0.5%
DOC, 0.1% SDS, with protease and phosphatase inhibitors). Muscle tissues were
lysed with the same buffer using ceramic beads. The concentration of the lysates
was measured with the BCA protein assay kit (Thermo Scientiﬁc) following the
manufacturer’s instructions. The samples were loaded to SDS-polyacrylamide gel
(Bio-Rad Laboratories), proteins were transferred to nitrocellulose membranes and
incubated with primary antibody against MyHC I (BA-D5, Developmental Studies
Hybridoma Bank, 1:250), Nfatc1 (YT5381, Immunoway, 1:1,000) or HSC70
(Santa Cruz Biotechnology, 1:5,000). For Prox1, cell lysates and soleus muscle
homogenates were ﬁrst immunoprecipitated with rabbit-anti-human Prox1
(in-house made, 1:1,000) antibody using Protein G beads, transferred to
nitrocellulose membranes and incubated with primary antibody for Prox1
(goat-anti-human, AF2727, R&D, 1:1,000). HRP-conjugated anti-mouse or
anti-goat secondary antibodies (Dako, 1:5,000) were used and the signal was
visualized by the SuperSignal West Pico or Femto Maximum Sensitivity Substrate
(Thermo Scientiﬁc). Alternatively, anti-rabbit IRDye800 and anti-mouse IRDye680
were used for detection (Licor, 1:10,000).
Histochemistry and immunoﬂuorescence. Mouse, rat (soleus, gastrocnemius
and tibialis anterior) and human (vastus lateralis) muscle samples were frozen in
liquid nitrogen-cooled isopentane in Tissue-Tek OCT. 10 mm sections were stained
with hematoxylin-eosin staining and using the following primary antibodies:
PROX1 (AF2727, R&D, 1:500 dilution), Laminin (Thermo Scientiﬁc, 1:500), CD31
(BD Biosciences, 1:500), MyHC I (BA-D5, Developmental Studies Hybridoma
Bank, 1:50), Pax3 and Pax7 (Developmental Studies Hybridoma Bank, 1:50)
and NCAM/CD56 (559043, BD Biosciences, 1:200), red ﬂuorescence protein
(600-901-379, Rockland Immunochemicals, 1:500) and Ki67 (Leica, 1:200).
For signal detection, Alexa Fluor 488, 594, 633- or 647-conjugated secondary
antibodies (Molecular Probes, 1:500) were used. Nuclei were labelled with DAPI.
C2C12 cells and primary human myoblasts were ﬁxed with 4% paraformaldehyde
for 10–15min and stained with phalloidin (F-actin, Molecular Probes, 1:500) for
cell morphology and desmin antibody (Millipore, 1:500) to conﬁrm that the human
primary cells were of muscle origin. C2C12 cells were also stained with Nfatc1
(YT5381, Immunoway, 1:100) and myosin (MF-20, Developmental Studies
Hybridoma Bank, 1:50) antibodies. For proliferation studies, shScr and shProx1
C2C12 cells were incubated for 4 h on coverslips with EdU and stained according
to the manufacturer’s protocol (Molecular Probes). Samples were imaged using
Leica DM LB light microscope, Zeiss Axioplan ﬂuorescent microscope and Zeiss
LSM 780 confocal microscope. Images were processed and analysed with ImageJ
(NIH).
Statistical analysis. Statistical comparison of two groups was done by Student’s
two-tailed unpaired t-test or one-way analysis of variance (with repeated mea-
surements in C2C12 cell differentiation experiment) followed by Tukey’s post hoc
test for more groups using the Prism 6.0 software. Data was checked for normality
and equal variances between groups. Po0.05 was considered as statistically
signiﬁcant and the signiﬁcance is marked by *Po0.05, **Po0.01, and ***Po0.001.
The required sample size was calculated based on the similar experiments and
analyses carried out previously. The number of animals in each experiment is
stated in the respective ﬁgure legends. All in vitro experiments were replicated
2–4 times and the main animal experiments were conducted twice or using
different species. Samples or animals were excluded from the data analysis with
pre-established criteria, if they deviated more than 2 s.d. from the group mean.
Data availability. The microarray data have been submitted to the GEO database,
under the series accession number GSE69199.
References
1. Cheung, T. H. & Rando, T. A. Molecular regulation of stem cell quiescence.
Nat. Rev. Mol. Cell Biol. 14, 329–340 (2013).
2. Yin, H., Price, F. & Rudnicki, M. A. Satellite cells and the muscle stem cell
niche. Physiol. Rev. 93, 23–67 (2013).
3. Buckingham, M. & Rigby, P. W. Gene regulatory networks and transcriptional
mechanisms that control myogenesis. Dev. Cell 28, 225–238 (2014).
4. Almada, A. E. & Wagers, A. J. Molecular circuitry of stem cell fate in skeletal
muscle regeneration, ageing and disease. Nat. Rev. Mol. Cell Biol. 17, 267–279
(2016).
5. Schiafﬁno, S. & Reggiani, C. Fiber types in mammalian skeletal muscles.
Physiol. Rev. 91, 1447–1531 (2011).
6. Elsir, T., Smits, A., Lindstrom, M. S. & Nister, M. Transcription factor PROX1:
its role in development and cancer. Cancer Metastasis Rev. 31, 793–805 (2012).
7. Oliver, G. et al. Prox 1, a prospero-related homeobox gene expressed during
mouse development. Mech. Dev. 44, 3–16 (1993).
8. Zinovieva, R. D. et al. Structure and chromosomal localization of the human
homeobox gene Prox 1. Genomics 35, 517–522 (1996).
9. Wigle, J. T. & Oliver, G. Prox1 function is required for the development of the
murine lymphatic system. Cell 98, 769–778 (1999).
10. Sosa-Pineda, B., Wigle, J. T. & Oliver, G. Hepatocyte migration during liver
development requires Prox1. Nat. Genet. 25, 254–255 (2000).
11. Risebro, C. A. et al. Prox1 maintains muscle structure and growth in the
developing heart. Development 136, 495–505 (2009).
12. Wigle, J. T., Chowdhury, K., Gruss, P. & Oliver, G. Prox1 function is crucial for
mouse lens-ﬁbre elongation. Nat. Genet. 21, 318–322 (1999).
13. Burke, Z. & Oliver, G. Prox1 is an early speciﬁc marker for the developing liver
and pancreas in the mammalian foregut endoderm. Mech. Dev. 118, 147–155
(2002).
14. Roy, S., Wolff, C. & Ingham, P. W. The u-boot mutation identiﬁes a Hedgehog-
regulated myogenic switch for ﬁber-type diversiﬁcation in the zebraﬁsh
embryo. Genes Dev. 15, 1563–1576 (2001).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13124
10 NATURE COMMUNICATIONS | 7:13124 | DOI: 10.1038/ncomms13124 | www.nature.com/naturecommunications
15. An, C. I., Dong, Y. & Hagiwara, N. Genome-wide mapping of Sox6 binding
sites in skeletal muscle reveals both direct and indirect regulation of muscle
terminal differentiation by Sox6. BMC Dev. Biol. 11, 59 (2011).
16. Petchey, L. K. et al. Loss of Prox1 in striated muscle causes slow to fast skeletal
muscle ﬁber conversion and dilated cardiomyopathy. Proc. Natl Acad. Sci. USA
111, 9515–9520 (2014).
17. Wiener, Z. et al. Prox1 promotes expansion of the colorectal cancer stem
cell population to fuel tumor growth and ischemia resistance. Cell Rep. 8,
1943–1956 (2014).
18. Petrova, T. V. et al. Transcription factor PROX1 induces colon cancer
progression by promoting the transition from benign to highly dysplastic
phenotype. Cancer Cell 13, 407–419 (2008).
19. McCarthy, J. J., Srikuea, R., Kirby, T. J., Peterson, C. A. & Esser, K. A. Inducible
Cre transgenic mouse strain for skeletal muscle-speciﬁc gene targeting. Skelet.
Muscle 2, 8 (2012).
20. Bassel-Duby, R. & Olson, E. N. Signalling pathways in skeletal muscle
remodeling. Annu. Rev. Biochem. 75, 19–37 (2006).
21. Kingsbury, T. J. & Cunningham, K. W. A conserved family of calcineurin
regulators. Genes Dev. 14, 1595–1604 (2000).
22. Kielbasa, O. M. et al. Myospryn is a calcineurin-interacting protein that
negatively modulates slow-ﬁber-type transformation and skeletal muscle
regeneration. FASEB J. 25, 2276–2286 (2011).
23. Frey, N. et al. Calsarcin-2 deﬁciency increases exercise capacity in mice through
calcineurin/NFAT activation. J. Clin. Invest. 118, 3598–3608 (2008).
24. Seto, J. T. et al. ACTN3 genotype inﬂuences muscle performance through the
regulation of calcineurin signalling. J. Clin. Invest. 123, 4255–4263 (2013).
25. Bjornson, C. R. et al. Notch signalling is necessary to maintain quiescence in
adult muscle stem cells. Stem Cells 30, 232–242 (2012).
26. Mourikis, P. et al. A critical requirement for notch signalling in maintenance of
the quiescent skeletal muscle stem cell state. Stem Cells 30, 243–252 (2012).
27. Wen, Y. et al. Constitutive Notch activation upregulates Pax7 and promotes the
self-renewal of skeletal muscle satellite cells. Mol. Cell. Biol. 32, 2300–2311
(2012).
28. Kang, J. et al. An exquisite cross-control mechanism among endothelial cell fate
regulators directs the plasticity and heterogeneity of lymphatic endothelial cells.
Blood 116, 140–150 (2010).
29. Potthoff, M. J. et al. Histone deacetylase degradation and MEF2 activation
promote the formation of slow-twitch myoﬁbers. J. Clin. Invest. 117, 2459–2467
(2007).
30. Schiafﬁno, S., Sandri, M. & Murgia, M. Activity-dependent signalling pathways
controlling muscle diversity and plasticity. Physiology 22, 269–278 (2007).
31. Chin, E. R. et al. A calcineurin-dependent transcriptional pathway controls
skeletal muscle ﬁber type. Genes Dev. 12, 2499–2509 (1998).
32. Naya, F. J. et al. Stimulation of slow skeletal muscle ﬁber gene expression by
calcineurin in vivo. J. Biol. Chem. 275, 4545–4548 (2000).
33. McCullagh, K. J. et al. NFAT is a nerve activity sensor in skeletal muscle and
controls activity-dependent myosin switching. Proc. Natl Acad. Sci. USA 101,
10590–10595 (2004).
34. Stergiopoulos, A., Elkouris, M. & Politis, P. K. Prospero-related homeobox 1
(Prox1) at the crossroads of diverse pathways during adult neural fate
speciﬁcation. Front. Cell Neurosci. 8, 454 (2014).
35. Sabine, A. et al. Mechanotransduction, PROX1, and FOXC2 cooperate to
control connexin37 and calcineurin during lymphatic-valve formation. Dev.
Cell 22, 430–445 (2012).
36. Brack, A. S., Conboy, I. M., Conboy, M. J., Shen, J. & Rando, T. A. A temporal
switch from notch to Wnt signalling in muscle stem cells is necessary for
normal adult myogenesis. Cell Stem Cell 2, 50–59 (2008).
37. Kaltezioti, V. et al. Prox1 regulates the notch1-mediated inhibition of
neurogenesis. PLoS Biol. 8, e1000565 (2010).
38. Bolado-Carrancio, A., Riancho, J. A., Sainz, J. & Rodriguez-Rey, J. C. Activation
of nuclear receptor NR5A2 increases Glut4 expression and glucose metabolism
in muscle cells. Biochem. Biophys. Res. Commun. 446, 614–619 (2014).
39. Harvey, N. L. et al. Lymphatic vascular defects promoted by Prox1
haploinsufﬁciency cause adult-onset obesity. Nat. Genet. 37, 1072–1081 (2005).
40. Srinivasan, R. S. et al. Lineage tracing demonstrates the venous origin of the
mammalian lymphatic vasculature. Genes Dev. 21, 2422–2432 (2007).
41. Skrobuk, P., von Kraemer, S., Semenova, M. M., Zitting, A. & Koistinen, H. A.
Acute exposure to resveratrol inhibits AMPK activity in human skeletal muscle
cells. Diabetologia 55, 3051–3060 (2012).
42. Yugawa, T. et al. Regulation of Notch1 gene expression by p53 in epithelial
cells. Mol. Cell. Biol. 27, 3732–3742 (2007).
43. Ragusa, S. et al. PROX1 promotes metabolic adaptation and fuels outgrowth of
Wnt(high) metastatic colon cancer cells. Cell Rep. 8, 1957–1973 (2014).
44. Kallio, M. A. et al. Chipster: user-friendly analysis software for microarray and
other high-throughput data. BMC Genomics 12, 507 (2011).
45. Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative
phosphorylation are coordinately downregulated in human diabetes. Nat.
Genet. 34, 267–273 (2003).
46. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression proﬁles. Proc. Natl Acad.
Sci. USA 102, 15545–15550 (2005).
47. Chemello, F. et al. Microgenomic analysis in skeletal muscle: expression
signatures of individual fast and slow myoﬁbers. PLoS ONE 6, e16807 (2011).
Acknowledgements
We thank Jenny Ho¨gstro¨m, Seppo Kaijalainen and Jianpin Cheng for their help with
the vector constructs, Dr Guillermo Oliver for kindly providing the Prox1ﬂ/ﬂ and
Prox1-CreERT2 mice and Dr Karyn Esser for the HSA-MerCreMer mice. Dr Juha Hulmi
kindly provided human skeletal muscle samples for histochemistry, Drs Tohru Kiyono
and Panagiotis Politis the Notch1-luciferase construct and Dr Jan Kitajewski the
Ad-hNotch1 construct. Kirsi Lintula, Maria Arrano de Kivikko, Tanja Laakkonen and
Tapio Tainola are acknowledged for their excellent technical help. We also thank the
Biomedicum Imaging Unit for microscope support and the AAV Gene Transfer and Cell
Therapy Core Facility of Biocentrum Finland for the AAV-vectors. The monoclonal
antibodies for Pax3, Pax7, MF-20 and Myh7 were obtained from the Developmental
Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The
University of Iowa, Department of Biology, Iowa City, IA 52242. The Jenny and Antti
Wihuri Foundation, the Academy of Finland (Centre of Excellence Program (271845,
K.A.), Marie Curie Actions of European Union’s Seventh Framework Programme
FP7/2007–2013 (Grant 317250 VESSEL), the Leducq Foundation (11CVD03, K.A.), the
Sigrid Juselius Foundation (Z.W., K.A.) and the Cancer Society of Finland (K.A. and
Z.W.) are acknowledged for funding. H.A.K. acknowledges funding from the Academy of
Finland (grant 258753) Liv och Ha¨lsa Foundation and Finska La¨karesa¨llskapet. Z.W.
currently receives funding from the Ja´nos Bolyai Fellowship (Hungarian Academy of
Sciences, BO/00068/15/8), the Semmelweis University Starting Grant (40148 11659) and
the National Research, Development and Innovation Ofﬁce (Hungary, OTKA-NN
118018).
Author contributions
R.K., I.S. and Z.W. planned and conducted the experiments, Y.H.N. and H.A.K. isolated
and provided the primary human myoblasts, T.V.P. provided essential reagents and
planned some of the experiments, and R.K. and K.A. designed the study and wrote the
paper.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Kivela¨, R. et al. The transcription factor Prox1 is essential for
satellite cell differentiation and muscle ﬁbre type regulation. Nat. Commun. 7, 13124
doi: 10.1038/ncomms13124 (2016).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2016
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13124 ARTICLE
NATURE COMMUNICATIONS | 7:13124 |DOI: 10.1038/ncomms13124 | www.nature.com/naturecommunications 11
